Pfizer Watchers Try To Read New CEO's Next Moves
Executive Summary
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
You may also be interested in...
Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says
Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.
Deals Of The Week: Cephalon/Mesoblast; GSK/MeiRui; Geron/Angiochem…
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Deals Of The Week: Cephalon/Mesoblast; GSK/MeiRui; Geron/Angiochem…
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.